See every side of every news story
Published loading...Updated

Nicox Announces Data Collection Complete, NCX 470 Phase 3b Whistler Glaucoma Trial

Summary by Eyewire+
Nicox announced today that the last patient completed their final visit in the Whistler phase 3b clinical trial investigating the efficacy of NCX470 to lower IOP. This marks the end of their data collection period.  NCX 470 (bimatoprost grenod) uses a dual mechanism of action—nitric oxide and a prostaglandin analog—to lower IOP. The Whistler phase 3b trial is a double-masked, placebo-controlled study that evaluated the effect of NCX470 on aqueou…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Eyewire+ broke the news in on Wednesday, March 19, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.